A Phase I Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Liposomal Bupivacaine for Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy
Open Access
- 8 November 2024
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 65 (4) , 441-451
Abstract
This trial assessed the pharmacokinetics, pharmacodynamics, and safety of liposomal bupivacaine given via ultrasound‐guided popliteal sciatic nerve block with or without immediate‐release bupivacaine hydrochloride in adults having bunionectomies. Forty‐five adults were enrolled into four sequential cohorts: (1) liposomal bupivacaine 266 mg with bupivacaine hydrochloride 50 mg; (2) liposomal bupivacaine 133 mg with bupivacaine hydrochloride 50 mg; (3) liposomal bupivacaine 266 mg; or (4) bupivacaine hydrochloride 100 mg. Outcomes included pharmacokinetics (e.g., bupivacaine maximum plasma concentration [Cmax]), onset and duration of motor and sensory nerve block, and safety. Liposomal bupivacaine admixed with bupivacaine hydrochloride produced biphasic bupivacaine plasma disposition profiles with two distinct peaks. Geometric mean Cmax of the early peak ranged from 235 to 421 ng/mL and the geometric mean of the late Cmax was ∼30%‐50% lower than the early peak. Median time to sensory block onset was 18 to 29 min in all cohorts. Sensory blocks lasted about twice as long with liposomal bupivacaine (median, 119‐167 h) than with bupivacaine hydrochloride alone (median, 67 h). There were no serious adverse events. In conclusion, liposomal bupivacaine provided prolonged sensory nerve block when given as popliteal sciatic nerve blocks with or without bupivacaine hydrochloride, and bupivacaine plasma concentrations were well below the lower bound of the toxicity threshold of 2000 ng/mL for all cohorts.Keywords
This publication has 20 references indexed in Scilit:
- A phase 3 active-controlled trial of liposomal bupivacaine via sciatic nerve block in the popliteal fossa after bunionectomyJournal of Clinical Anesthesia, 2024
- Probing the mechanism of bupivacaine drug release from multivesicular liposomesJournal of Controlled Release, 2019
- Systemic Safety of Liposomal Bupivacaine in Simultaneous Bilateral Total Knee ArthroplastyThe Journal of Arthroplasty, 2018
- American College of Foot and Ankle Surgeons® Clinical Consensus Statement: Perioperative ManagementThe Journal of Foot and Ankle Surgery, 2017
- Pharmacokinetic Profile and Tolerability of Liposomal Bupivacaine Following a Repeated Dose via Local Subcutaneous Infiltration in Healthy VolunteersClinical Drug Investigation, 2017
- Liposome Bupivacaine Femoral Nerve Block for Postsurgical Analgesia after Total Knee ArthroplastyAnesthesiology, 2016
- Pain Management for Elective Foot and Ankle Surgery: A Systematic Review of Randomized Controlled TrialsThe Journal of Foot and Ankle Surgery, 2015
- The Safety of Liposome Bupivacaine, A Novel Local Analgesic FormulationThe Clinical Journal of Pain, 2014
- Pharmacokinetic Profile of Liposome Bupivacaine Injection Following a Single Administration at the Surgical SiteClinical Drug Investigation, 2012
- A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplastyThe Knee, 2012